Audit Compensation Nominating and Corporate Governance
Larry Ellberger Chairman of the Board Financial Expert Member of Audit Committee   Member of Nominating and Corporate Governance Committee
Keith L. Brownlie Financial Expert Committee Chair for Audit Committee    
Former Partner, Ernst & Young LLP

Mr. Brownlie has been a director of Celldex since June 2017. He was employed by the accounting firm Ernst & Young LLP from 1974 to 2010, where he served as audit partner for numerous public companies and was the Life Sciences Industry Leader for the New York metropolitan area. He currently serves as a member of the boards of directors and chairman of the audit committees for two publicly-held biopharmaceutical companies—Soligenix, Inc. and RXi Pharmaceuticals Corporation, and he previously served in the same capacity for the publicly-held EpiCept Corporation and Cancer Genetics, Inc. Mr. Brownlie received a B.S. in Accounting from Lehigh University and is a Certified Public Accountant.


Herbert J. Conrad   Member of Compensation Committee Member of Nominating and Corporate Governance Committee
James J. Marino,, J.D.   Committee Chair for Compensation Committee  
Harry H. Penner, Jr., J.D., L.L.M. Member of Audit Committee Member of Compensation Committee  
Karen L. Shoos, J.D.     Committee Chair for Nominating and Corporate Governance Committee
Chair of the Board = Chair of the Board Committee Chair = Chair Committee Member = Member Financial Expert = Financial Expert
Chair of the Board = Chair of the Board
Committee Chair = Chair
Committee Member = Member
Financial Expert = Financial Expert

Stock transaction information provided by EDGAR Online. Celldex Therapeutics, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.